Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity March 28, 2025
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update March 11, 2025
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025 February 14, 2025
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU February 11, 2025
Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025 January 8, 2025
Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference January 6, 2025
